January 7, 2022 7:42am
I’d be BUYING some of the 52-week cell and gene therapy sector lows after the sector sunk, again
Pre-open indications: 11 BUYs and 1 SELL
What I provide is an intelligence daily. RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.
Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.
December jobs report came in short, well below of expectations
Dow futures are DOWN -0.14% (-49 points), S&P futures are DOWN -0.18% (-9 points) and NASDAQ futures are DOWN -0.50% (-80 points)
U.S. stock index futures are mixed and incrementally up during early morning trading on Friday, ahead of a key jobs report release,
European stocks were lower waiting “our” key jobs numbers,
Asia-Pacific stocks were mixed following heavy losses for some regional markets in the previous trading session.
Economic Data Docket: nonfarm payrolls report; economists are expecting the economy to have added 422,000 jobs in December. The unemployment rate is expected to come in at 4.1%.
Praying for a comeback, the oversold are making portfolios suffer.
The Dow fell 170 points, or 0.47%, while the S&P declined 4.53 points or -0.10% - both are on track for their first (1st) negative week in three (3) while the Nasdaq slid -19.31 or -0.13% for its seventh (7th) negative session in the last eight.
The stock market rally is under pressure, and Thursday didn't do anything to change that. The Nasdaq fell more than 1% intraday, approaching recent lows, before rebounding, briefly turning positive. But that's after sinking 1.3% on Tuesday and tumbling 3.3% on Wednesday, knifing through its 50-day moving average. <IBD>
If you didn’t remember what happen Thursday night and the last session of 2021’s close, you won’t be prepared for today’s session:
RegMed Investors’ (RMi) closing bell: “confluences, a junction of two positions of thought on the cell and gene therapy sector, BUY or SELL? I’d be BUYING 52-week lows as the sector sinks, again.” … https://www.regmedinvestors.com/articles/12246
Ebb and flow:
- January to date, 3 negative and 1 positive close
Companies in my headlights – It’s your decision; I provide an idea and context:
Probabilities versus aftermarket/pre-open share pricing indication moves:
Adverum Biotechnologies (ADVM) closed down flat at $1.73 with a positive +$0.02 or +1.16% pre-open indication after hitting a 52-week low of $1.67
Applied Genetic Technologies (AGTC) closed down -$0.02 to $1.81 with a positive +$0.05 or +2.76% after hitting a 52-week low of $1.80.
AxoGen (AXGN) closed up +$0.56 to $10.70 after Wednesday’s -$0.30 to $10.14, Tuesday’s +$0.46 to $10.44 and Monday’s +$0.61 or +6.51% to $9.98 with a positive +$1.28 or +11.96% pre-market indication,
Homology Medicine (FIXX) closed down -$0.08 to $3.53 after Wednesday’s -$0.22 or -5.74% to $3.61 with a positive +$0.03 or +0.849% pre-open indication after hitting a 52-week low of $3.56.
CRISPR Therapeutics (CRSP) closed down -$1.83 to $67.18 with a +$0.83 or +1.24% pre-open indication.
Editas Medicine (EDIT) closed down -$0.19 to $24.41 after Wednesday’s -$1.80 or -6.82% to $24.60 after Tuesday’s -$1.23 to $26.40 and Monday’s +$1.08 to $27.63 with a negative -$0.04 or -0.16% pre-open indication – could be early.
Sangamo Therapeutics (SGMO) closed down -$0.29 to $6.77 with a positive +$0.08 or +1.88% pre-open indication after hitting a 52-week low of $6.18
Global Blood Therapeutics (GBT) closed up +$0.74 to $28.41 after Wednesday’s -$1.66 or -5.66% to $27.67, Tuesday’s $29.33 and Monday’s $30.46 with a positive +$0.39 or +1.37% pre-open indication
uniQure NV (QURE) closed down -$1.19 or -5.75% to $19.52 after Tuesday’s $20.71 and Monday’s $21.50 with a NO pre-open indication.
BUY from SELL:
Ultragenyx (RARE) closed down -$4.17 to $79.39 after Wednesday’s +$0.37 to $83.56 with a positive +$0.31 or +0.39% pre-open indication.
Alnylam Pharmaceuticals (ALNY) closed down again -$0.49 to $151.00 after Wednesday’s -$10.14 or -6.14% to $155.09 and Tuesday’s -$8.68 or -4.99% to $165.23 with a positive +$0.42 or +0.28% pre-open indication.
Biostage (OTCQB: BSTG) closed flat with 1,165 shares traded after Wednesday’s +$0.01 with 262 shares traded, Tuesday’s +$0.02 with 1626 shares traded, Monday’s flat with 20 shares traded and last Friday’s down -$0.05 with 1,001 shares traded. Notice how the shares traded with and without the manipulated share pricing by volume stimulation; just a “House of Cards”?
The BOTTOM LINE: I hope NOT to be a broken record …
Reiterating, “Readers need to recite the black on white treatise as to how many times I am right to believe it.”
- The “BUY” zone is still questionable but, there’s room for oversold movement
- I am NOT changing my position, “Brace for more choppiness heading into the start of the year.”
- I used to think negativity was a state of mind. Now, having watched for long enough, I have come to realize that negativity can be a character trait
- The volatile nature of cell, gene and biotech stocks is a double-edged sword; these stocks can produce gains but, sustainability or lack thereof, has been a factor through 2021 that I believe will continue into 2022.
Boom or bust as many missed end-points incurring weighty losses if a drug trial fails to perform or comes to market without any following.
Risks are also due to the possibility that many products under development may never make it to market. Share pricings were NOT maintained in 2021, begetting the collapse of many a company’s pricings as months wore on.
- I say today what others won't, so you can do what others can't whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors
I still have a hang-up with investment bank target price rankings, they don’t take the daily, monthly, or even quarterly share pricing effects into consideration. Buy-side analysts work for funds that purchase or actively trade the securities they cover and even they have their lapses.
- I have “lived” on both sides and “find’ that “big spikes are common in these markets but, they are usually short in duration.”
So, my bottom of the Bottom Line, Investors should be extremely cautious about adding any new exposure.
The cell and gene therapy sector has a downside bias and is a dangerous “spot”; to play in. It's an environment that lures investors in, only to sell off sharply again.
- If you want to BUY, focus only on stocks that COULD show the potential of sustainability.
RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.
WHY do I keep reporting on Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.